Literature DB >> 16194800

Effect of sleep apnea on cognition and mood.

Baruch El-Ad1, Peretz Lavie.   

Abstract

Obstructive sleep apnea syndrome (OSAS) is a common disorder in adults and children, which is characterized by repetitive transient reversible upper airway obstructions during sleep. Due to disrupted sleep architecture and intermittent hypoxemia, OSAS leads to impaired daytime functioning in various neuropsychological and affective domains. The most common abnormalities are executive dysfunction, impaired vigilance, depression, and possibly anxiety and, in children, hyperactivity. Optimal treatment of OSAS with continuous positive airway pressure may reverse the cognitive and affective dysfunction, however, in some patients a residual impairment persists. This persistent deficit, despite effective treatment, raises the possibility of a remaining subtle structural brain damage; such damage has been demonstrated through the use of sensitive functional and other neuroimaging techniques. Prefrontal cortical damage may underlie the cognitive dysfunction in OSAS. Early recognition and treatment may prevent this untoward effect of OSAS.

Entities:  

Mesh:

Year:  2005        PMID: 16194800     DOI: 10.1080/09540260500104508

Source DB:  PubMed          Journal:  Int Rev Psychiatry        ISSN: 0954-0261


  41 in total

1.  Pulse wave amplitude drops during sleep are reliable surrogate markers of changes in cortical activity.

Authors:  Alexandre Delessert; Fabrice Espa; Andrea Rossetti; Gilles Lavigne; Mehdi Tafti; Raphael Heinzer
Journal:  Sleep       Date:  2010-12       Impact factor: 5.849

2.  Sleep apnea syndrome: improved detection of respiratory events and cortical arousals using oxymetry pulse wave amplitude during polysomnography.

Authors:  André Zacharia; José Haba-Rubio; Raphaël Simon; Gregor John; Pascal Jordan; Alda Fernandes; Jean-Michel Gaspoz; Jean-Georges Frey; Jean-Marie Tschopp
Journal:  Sleep Breath       Date:  2008-03       Impact factor: 2.816

3.  Depressive Symptoms before and after Treatment of Obstructive Sleep Apnea in Men and Women.

Authors:  Cass Edwards; Sutapa Mukherjee; Laila Simpson; Lyle J Palmer; Osvaldo P Almeida; David R Hillman
Journal:  J Clin Sleep Med       Date:  2015-09-15       Impact factor: 4.062

Review 4.  Obstructive sleep apnea and cardiovascular disease: role of the metabolic syndrome and its components.

Authors:  Girardin Jean-Louis; Ferdinand Zizi; Luther T Clark; Clinton D Brown; Samy I McFarlane
Journal:  J Clin Sleep Med       Date:  2008-06-15       Impact factor: 4.062

Review 5.  Sleep as a Therapeutic Target in the Aging Brain.

Authors:  Thierno M Bah; James Goodman; Jeffrey J Iliff
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

6.  Sleep disturbances in prepubertal children with attention deficit hyperactivity disorder: a home polysomnography study.

Authors:  Reut Gruber; Tong Xi; Sonia Frenette; Manon Robert; Phetsamone Vannasinh; Julie Carrier
Journal:  Sleep       Date:  2009-03       Impact factor: 5.849

7.  A community-oriented framework to increase screening and treatment of obstructive sleep apnea among blacks.

Authors:  Natasha J Williams; Girardin Jean-Louis; Joeseph Ravenell; Azizi Seixas; Nadia Islam; Chau Trinh-Shevrin; Gbenga Ogedegbe
Journal:  Sleep Med       Date:  2015-09-25       Impact factor: 3.492

Review 8.  Pharmacology of vagal afferent influences on disordered breathing during sleep.

Authors:  David W Carley; Miodrag Radulovacki
Journal:  Respir Physiol Neurobiol       Date:  2008-12-10       Impact factor: 1.931

9.  Obstructive sleep apnea risk and psychological health among non-Hispanic blacks in the Metabolic Syndrome Outcome (MetSO) cohort study.

Authors:  Mirnova E Ceïde; Natasha J Williams; Azizi Seixas; Samantha K Longman-Mills; Girardin Jean-Louis
Journal:  Ann Med       Date:  2015-11-22       Impact factor: 4.709

Review 10.  Targeted drug delivery to treat pain and cerebral hypoxia.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Pharmacol Rev       Date:  2013-01-23       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.